615261-85-3

Upstream product

• 4792-15-8 Pentaethylene glycol 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 209542-21-2 2,2-dimethyl-3,3-diphenyl-4,7,10,13,16-pentaoxa-3-silaoctadecan-18-oic acid 
• 869893-61-8 [2-(2-{2-[2-(tert-Butyl-diphenyl-silanyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-acetic acid (S)-2-((5R,8R,9S,10S,13S,14S,17R)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-propyl ester 
• 869893-57-2 [2-(2-{2-[2-(tert-Butyl-diphenyl-silanyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-acetic acid (S)-2-((5S,8R,9S,10S,13S,14S)-10,13-dimethyl-3-oxo-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-propyl ester 
• 869893-58-3 [2-(2-{2-[2-(tert-Butyl-diphenyl-silanyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-acetic acid (S)-2-((3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-propyl ester 
• 869893-59-4 [2-(2-{2-[2-(tert-Butyl-diphenyl-silanyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-acetic acid (S)-2-((3S,5S,8R,9S,10S,13S,14S,17R)-3-hydroxy-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-17-yl)-propyl ester 
• 869893-64-1 [2-(2-{2-[2-(tert-Butyl-diphenyl-silanyloxy)-ethoxy]-ethoxy}-ethoxy)-ethoxy]-acetic acid (3S,5S,8R,9S,10S,13S,14S,17R)-17-((S)-2-acetoxy-1-methyl-ethyl)-10,13-dimethyl-hexadecahydro-cyclopenta[a]phenanthren-3-yl ester 
• 86770-68-5 2-[2-[2-[2-(2-azidoethoxy)ethoxy]ethoxy]ethoxy]ethanol 

Relevant academic research and scientific papers

A novel approach for preparing disulfide-rich peptide-KLH conjugate applicable to the antibody production

To produce the antiserum against a small peptide, the target peptide-keyhole limpet hemocyanine (KLH) conjugate is generally used as an antigen, although the disulfide-rich peptide-KLH conjugate is still difficult to prepare. In our previous study, we hav

Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis

We report the synthesis and evaluation of a series of cell-permeable and N- versus O-selective sialyltransferase inhibitors. Inhibitor design entailed the functionalization of lithocholic acid at C(3) and at the cyclopentane ring side chain. Among the series, FCW34 and FCW66 were shown to inhibit MDA-MB-231 cell migration as effectively as ST3GALIII-gene knockdown did. FCW34 was shown to inhibit tumor growth, reduce angiogenesis, and delay cancer cell metastasis in animal models. Furthermore, FCW34 inhibited vessel development and suppressed angiogenic activity in transgenic zebrafish models. Our results provide clear evidence that FCW34-induced sialyltransferase inhibition reduces cancer cell metastasis by decreasing N-glycan sialylation, thus altering the regulation of talin/integrin/FAK/paxillin and integrin/NFκB signaling pathways.

CEREBLON LIGANDS AND BIFUNCTIONAL COMPOUNDS COMPRISING THE SAME

The description relates to cereblon E3 ligase binding compounds, including bifunctional compounds comprising the same, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present disclosure. In particular, the description provides compounds, which contain on one end a ligand which binds to the cereblon E3 ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. Compounds can be synthesized that exhibit a broad range of pharmacological activities consistent with the degradation/inhibition of targeted polypeptides of nearly any type.

Steroid-based head-to-tail amphiphiles as effective iono- and protonophores

The synthesis of five steroid-oligo(ethyleneglycol) conjugates (1-5) has been accomplished starting from commercially available epi-androsterone (8) and known 3β-[(tert-butyldiphenylsilyl)oxy]-5α-23,24-bisnorchol-16-en- 6α,7β,22-triol (27). The synthetic